You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》北海康成(01228.HK)公開發售超購近1倍 一手中籤率66%
內地專注於罕見病的生物醫藥商北海康成(01228.HK)公布招股結果,每股發售價定為12.18元,香港公開發售部分錄得超額認購約0.97倍。每手1,000股計,一手中籤率65.99%。該股將於明日(10日)掛牌。摩根士丹利亞洲及富瑞金融集團香港為聯席保薦人。 公司引入基石投資者包括RA Capital、Hudson Bay、Janus Investors、General Atlantic、藥明生物(02269.HK)、瑞華資本及Belinda A. Termeer,合共認購3,836.9萬股公司股份,佔緊隨全球發售完成後的股本約9.05%。 是次上市料淨集資約6.04億元,約45.4%擬用於核心產品候選藥物CAN008的現有及日後研發、CMC開發以及生產;約24%用於產品管線中的主要產品及候選產品;約1.8%用於產品管線中其他非基因療法產品及候選產品的現有及日後研發;約12%用於為CAN201、CAN202及其他基因治療項目的現有及日後研發;16.8%用於為研發及其他一般業務用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account